Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications
Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.
Journal: Future oncology (London, England)
Published: July 06, 2026
Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.
Journal: Advances in therapy
Published: May 08, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Journal: Blood cancer journal
Published: January 28, 2026
Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024).
Journal: Leukemia & lymphoma
Published: January 19, 2026
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: December 10, 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: June 19, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Journal: Blood cancer journal
Published: September 05, 2024
Last Updated: 09/26/2026